LumiMeds review

The catalogue should be read one purchase at a time

LumiMeds currently lists compounded semaglutide, tirzepatide and NAD+ as available. The longevity page marks sermorelin as coming soon. A future listing should not be counted as a service a reader can currently receive, and the separate product plans should not be mistaken for one inclusive prevention package. ^{[1] [2] [3] [4] [5]}

The platform facilitates care from independent providers and fulfillment through pharmacy partners. That can be practical access for a defined need. It does not establish that an additional compound, a broader catalogue or a wellness label improves the result of existing care. ^[7]

Compare the actual scope of care in our health-service comparisons.

For a focused weight-care service and its financial exit, compare our MD Exam review.

A flat price does not answer every financial question

Current offers show $89 monthly for semaglutide, $125 for tirzepatide and $133 for NAD+. Provider review, contact and delivery are described as included, without a separate advertised membership charge. The selected invoice still needs to identify the product, term total, debit schedule and next renewal. ^{[1] [2] [4] [5]}

The linked membership terms describe full-term financial obligations, whether prepaid or paid in installments, and reserve pricing changes after notice. These provisions need to be reconciled with the no-membership, price-locked and flexibility advertising for the specific purchase. Payment convenience is not proof of an unrestricted exit. ^{[1] [6]}

Keep separate purchases visible with the complete care-cost planner.

The proposed preparation needs a consistent description

The NAD+ product page identifies Olympia as the source and describes a 1,000 mg vial, while its monthly frequency differs from weekly wording in the longevity catalogue. The semaglutide page also includes dual-receptor and escalation text inconsistent with its own product identification. Have the actual prescriber and dispenser settle the preparation and instructions; neither page should become a self-selected regimen. ^{[2] [3] [4]}

FDA explains that compounds do not receive its premarket safety, effectiveness and quality review. A facility-registration statement is not approval of the finished product. The useful outcome question concerns the exact preparation and clinical purpose, rather than a claim about cellular energy or a brand-associated ingredient. ^[10]

Define a meaningful outcome beyond the scale with the evidence on lean mass and physical function.

The regulatory history has a specific date and product scope

FDA’s September 9, 2025 LumiMeds warning letter concerned compounded semaglutide and tirzepatide advertising that implied sameness with approved products. It is a historical record of claims reviewed at that time, not a test result for a current shipment and not a NAD+ finding. ^[9]

Current pages state that compounds are not FDA approved, and the expanded semaglutide identity answer distinguishes them from branded products. That change in wording is not a finding of current regulatory clearance. FDA’s current GLP-1 guidance also ties compounding to medical needs an approved drug cannot meet; a lower price does not establish that need. ^{[4] [5] [11]}

Keep branded-product outcomes specific with the SELECT cardiovascular evidence.

Follow-up should test whether the care remains useful

The NAD+ FAQ describes response review after the first cycle; the semaglutide FAQ describes review after the initial treatment period. The general FAQ allows live or asynchronous evaluation depending on state rules. Establish what contact and reassessment the selected plan actually provides, rather than assume a comprehensive preventive visit. ^{[2] [4] [8]}

The homepage’s weight projection uses self-reported tirzepatide patient data and is explicitly not a clinical trial. The featured testimonials are disclosed as compensated. Neither supports a personal forecast, a clinical benefit from NAD+, or a conclusion about years of healthy life. ^[1]

Consider the continuing care question alongside the evidence after GLP-1 treatment stops.

The financial exit belongs beside the benefit claim

A provider’s medical non-approval can trigger a full refund under the advertised policy. General terms separately describe a $100 cancellation fee for other requests and make pharmacy-submitted orders final; shipped medication is not refundable. A fee is not a guarantee that an already processed order can be reversed. ^{[1] [7]}

The membership document also restricts mid-term exits and keeps the full commitment payable. Clarify which provisions govern the chosen plan before enrolling, especially when flexibility is essential. Delivery issues require timely reporting with the requested order, tracking, lot and photographic details within forty-eight hours. ^{[6] [7]}

For another catalogue with separate product commitments, compare our 50 Stars Health review.

Choose for a defined need, not for the promise of living longer

LumiMeds can be compared with 50 Stars Health for separate prescribed wellness and weight-care products. LifeMD provides another comparison when a focused weight-care relationship and branded-medication access support are the useful additions. Existing primary care may already do the work the reader needs.

I would choose only after the actual preparation, follow-up and financial commitment agree with the proposed purpose. A compact monthly price and a longevity heading are not enough to justify adding treatment. The service should earn its place through a concrete care need and terms the buyer understands.

For focused weight care and access support, read our LifeMD review.

Understanding the cost

Advertised monthly rates: semaglutide $89, tirzepatide $125 and NAD+ $133. These are separate purchases, not one combined membership. Obtain the actual total, term, payment dates, renewal and applicable cancellation provisions. Linked membership terms describe fixed-term obligations and pricing changes after notice; general terms include a $100 cancellation fee outside medical non-approval. ^{[1] [2] [3] [4] [5] [6] [7]}